Thank you Flipper and DD for your answers. If we obtain enough evidence of CSF-1R's utility in the combo and/or that keytruda is a plus, than Merck is the BP with the partnership/BO advantage. Otherwise I am looking forward to a fierce BP competition for NWBO's favors and that is also not a bad alternative.